G-protein coupled receptors (GPCRs) that bind catecholamines (noradrenaline and adrenaline), serving as the molecular targets through which the sympathetic nervous system exerts its effects on virtually every organ. Classified into α-adrenoreceptors (α1, α2) and β-adrenoreceptors (β1, β2, β3), each subtype couples to different G-proteins and triggers distinct intracellular cascades. Tissue-specific expression patterns create a mosaic of sympathetic responsiveness across the body.
Think of adrenoreceptors as a building's control panel with two main sections—alpha and beta switches—each controlling different building systems when the fire alarm (stress) goes off.
The α1 switches are like sprinkler valves that CLOSE when activated—they tighten blood vessel pipes, redirect water pressure (blood flow) away from the skin and gut toward muscles and brain. They also dilate your pupils like emergency floodlights turning on.
The α2 switches are the negative feedback thermostats—they sense when the alarm is TOO loud and turn down the noradrenaline production to prevent the system from overheating. They're located on the nerve endings themselves, saying "okay, we get it, enough alarm already."
The β1 switches are in the boiler room (heart)—when activated, they crank up the furnace: faster pumping, harder contractions, more heat output. Your heart becomes a racecar engine.
The β2 switches are the ventilation system—they open air ducts (bronchodilation), dilate certain pipes (vasodilation in muscles), and unlock the fuel storage (mobilize glucose and fats). They prepare the building for maximum performance.
The β3 switches are in the backup generator room (brown adipose tissue)—they fire up fat burning to generate heat and energy when you need extra metabolic power.
All these switches respond to the SAME alarm signal (catecholamines), but each does something completely different depending on where it's located and which G-protein it's wired to.
¶ Receptor Subtypes and G-Protein Coupling
α1-Adrenoreceptors (Gq-coupled):
- Activation → Gq protein activation → phospholipase C (PLC) activation → IP₃ + DAG production → Calcium release from endoplasmic reticulum + PKC activation
- Ca²⁺ ↑ → smooth muscle contraction (vasoconstriction, mydriasis, urethral sphincter tone)
- Primary locations: vascular smooth muscle, iris dilator muscle, urethral sphincter, prostate
- Effect: vasoconstriction, increased peripheral resistance, pupil dilation
α2-Adrenoreceptors (Gi-coupled):
- Activation → Gi protein activation → adenylyl cyclase inhibition → CAMP ↓
- Also opens K⁺ channels and closes Ca²⁺ channels → hyperpolarization and reduced neurotransmitter release
- Presynaptic location: negative feedback autoreceptors on sympathetic nerve terminals
- Postsynaptic locations: brain (sedation, analgesia), pancreatic β-cells (insulin inhibition), platelets (aggregation)
- Effect: sympathetic tone reduction, decreased noradrenaline release, central sedation
β1-Adrenoreceptors (Gs-coupled):
- Activation → Gs protein activation → adenylyl cyclase activation → CAMP ↑ → PKA activation
- In heart: PKA phosphorylates L-type Ca²⁺ channels, phospholamban, troponin I, myosin-binding protein C
- Result: increased heart rate (chronotropy), increased contractility (inotropy), increased conduction velocity (dromotropy)
- Primary location: cardiac myocytes (60% of cardiac β-receptors are β1)
- Also in kidney: renin release → activation of RAA-system
β2-Adrenoreceptors (Gs-coupled):
- Activation → Gs → CAMP ↑ → PKA activation
- In smooth muscle: PKA phosphorylates myosin light chain kinase (inactivation) → relaxation
- Effects: bronchodilation, vasodilation (skeletal muscle, liver), uterine relaxation, tremor
- Metabolic effects: glycogenolysis (liver, muscle), Lipolysis (adipose), insulin secretion (pancreatic β-cells)
- Primary locations: bronchial smooth muscle, vascular smooth muscle in skeletal muscle, liver, skeletal muscle, adipocytes
β3-Adrenoreceptors (Gs-coupled):
- Activation → Gs → cAMP ↑ → PKA → hormone-sensitive lipase activation
- Triggers Lipolysis in white and brown adipose tissue
- In brown fat: activates UCP1 expression → non-shivering thermoregulation
- Emerging role in bladder relaxation (detrusor muscle)
- Lower affinity for catecholamines than β1/β2—requires higher concentrations
graph TD
A[Noradrenaline/Adrenaline] --> B["α1-Adrenoreceptor"]
A --> C["α2-Adrenoreceptor"]
A --> D["β1-Adrenoreceptor"]
A --> E["β2-Adrenoreceptor"]
A --> F["β3-Adrenoreceptor"]
B --> B1[Gq activation]
B1 --> B2["PLC → IP₃ + DAG"]
B2 --> B3["Ca²⁺ ↑"]
B3 --> B4["Vasoconstriction<br/>Mydriasis"]
C --> C1[Gi activation]
C1 --> C2["cAMP ↓"]
C2 --> C3["Negative feedback<br/>Sedation"]
D --> D1[Gs activation]
D1 --> D2["cAMP ↑"]
D2 --> D3[PKA activation]
D3 --> D4["HR ↑<br/>Contractility ↑"]
E --> E1[Gs activation]
E1 --> E2["cAMP ↑"]
E2 --> E3[PKA activation]
E3 --> E4["Bronchodilation<br/>Vasodilation<br/>Lipolysis"]
F --> F1[Gs activation]
F1 --> F2["cAMP ↑"]
F2 --> F3[PKA activation]
F3 --> F4["Lipolysis<br/>Thermogenesis"]
¶ Differential Ligand Affinity
- α-receptors: Noradrenaline > Adrenaline (except α2B where equal)
- β1-receptors: Noradrenaline ≈ Adrenaline (equal affinity)
- β2-receptors: Adrenaline >> Noradrenaline
- β3-receptors: Noradrenaline ≈ Adrenaline (both require higher concentrations)
This differential affinity creates a dose-response hierarchy: low catecholamine levels activate β1 and α-receptors; high levels recruit β2; very high levels activate β3.
¶ Receptor Desensitization and Regulation
Chronic sympathetic activation triggers:
- Phosphorylation by G-protein receptor kinases (GRKs) → β-arrestin binding → receptor internalization
- Downregulation of receptor number (hours to days of exposure)
- Uncoupling from G-proteins without change in receptor number
- Result: Catecholamine Resistance—the need for higher catecholamine levels to achieve same effect (seen in heart failure, chronic stress)
¶ Disease Targets and Pharmacology
β-blockers (β1-selective: metoprolol, bisoprolol; non-selective: propranolol):
- Mechanism: competitive antagonism of β-adrenoreceptors
- Indications: hypertension, heart failure, arrhythmias, post-MI, migraine prophylaxis, anxiety (propranolol for performance anxiety)
- cPNI relevance: chronic sympathetic dominance requires addressing root causes (stress, chronic inflammation, insulin resistance) not just blocking receptors
- Side effects reveal receptor distribution: β2-blockade → bronchoconstriction (avoid in asthma), reduced glycogenolysis (mask hypoglycemia in diabetics), cold extremities
β2-agonists (short-acting: salbutamol/albuterol; long-acting: salmeterol):
- Bronchodilation for asthma, COPD
- Tocolytic (delay preterm labor via uterine relaxation)
- Anabolic in muscle (used illegally in livestock)—stimulate muscle protein synthesis via cAMP-PKA-mTOR axis
α1-blockers (doxazosin, tamsulosin):
- Vasorelaxation for hypertension
- Prostate/urethral relaxation for benign prostatic hyperplasia
- May worsen orthostatic hypotension in elderly or volume-depleted patients
α2-agonists (Clonidine, dexmedetomidine):
- Central sympathetic suppression (antihypertensive)
- Sedation, analgesia (used in anesthesia)
- ADHD (guanfacine)—improve prefrontal cortex function via α2A receptors
¶ Connective Tissue and Fascial Tension
From course material: "When stress hormones bind these receptors, they increase tension in the tissue—connective tissue becomes physically TIGHTER and STIFFER under sympathetic activation."
- Mechanism: α1-adrenoreceptor activation in fascial myofibroblasts → Calcium-dependent contractile response
- Clinical relevance: chronic sympathetic tone → chronic fascial restriction → chronic pain, reduced mobility
- Seen in: fibromyalgia, chronic stress, PTSD, frozen shoulder
- Intervention: must address sympathetic drivers (psychological stress, inflammation, sleep deprivation) AND mechanoreceptor input (manual therapy, movement, breathing)
¶ Polymorphisms and Individual Variation
β2-adrenoreceptor polymorphisms:
- Gly16Arg (most common): Arg16 variant → enhanced agonist-promoted downregulation → reduced response to chronic β2-agonist therapy in asthma
- Gln27Glu: Glu27 variant → resistance to downregulation → better long-term response to β2-agonists
- Clinical implication: pharmacogenomic variation in asthma control, obesity risk (β2 mediates lipolysis), cardiovascular risk
α2-adrenoreceptor polymorphisms:
- Deletion variant → reduced negative feedback → higher sympathetic tone → increased cardiovascular risk, salt-sensitive hypertension
¶ Evolutionary and Metamodel Context
Selfish Brain/Selfish Immune System:
- Adrenoreceptor-mediated glucose mobilization (β2) and cardiovascular prioritization (β1 cardiac, α1 peripheral) serve brain energy demands during stress
- Catecholamine-induced leukocytosis (β2-mediated) recruits immune cells to circulation → "stress-induced immunoenhancement" preparing for injury/infection
- Chronic activation → allostatic load: receptor desensitization, insulin resistance, immune exhaustion
Evolutionary Mismatch:
- System designed for acute intermittent threats (predator, injury, cold exposure)
- Modern chronic activation (psychological stress, sleep deprivation, chronic inflammation, electronic stimulation) → sympathetic dominance
- Result: receptor resistance requiring higher catecholamine levels → vicious cycle of dysregulation
Clinical Threshold Recognition:
- Heart rate variability (HRV) <50 ms RMSSD → sympathetic dominance
- Resting heart rate >75 bpm → chronic β1 activation (cardiovascular risk ↑)
- Orthostatic hypotension → α1 receptor desensitization or dysfunction
- Cold hands/feet despite normal thyroid → α1-mediated peripheral vasoconstriction (chronic stress pattern)
Rather than pharmaceutical blockade as first-line:
- Address catecholamine drivers: psychological stress (CBT, mindfulness), chronic inflammation (diet, gut health), sleep disorders
- Parasympathetic activation: vagus nerve stimulation (cold exposure, singing, slow breathing), Heart rate variability training
- Receptor resensitization: intermittent fasting, exercise variability (avoid chronic high-intensity), adequate recovery
- Connective tissue: fascial release, movement, heat therapy to reduce α1-mediated contractile tone
- Two main families: α (α1, α2) and β (β1, β2, β3)—all are GPCRs with 7 transmembrane domains
- α1 (Gq): vasoconstriction, mydriasis, prostate contraction; blocked by doxazosin, prazosin
- α2 (Gi): negative feedback on sympathetic terminals, sedation, analgesia; activated by clonidine
- β1 (Gs): 60% of cardiac β-receptors; increased HR and contractility; blocked by metoprolol
- β2 (Gs): bronchodilation, skeletal muscle vasodilation, lipolysis, glycogenolysis; activated by salbutamol
- β3 (Gs): adipose lipolysis, thermogenesis in brown fat; requires higher catecholamine concentrations
- Affinity hierarchy: β2 prefers adrenaline; α and β1 prefer noradrenaline; β3 needs high levels of either
- Chronic activation → receptor desensitization (hours) and downregulation (days)—mechanism of catecholamine resistance
- Gly16Arg β2 polymorphism affects asthma treatment response and obesity risk
- Fascial myofibroblasts express α1-adrenoreceptors → sympathetic tone increases tissue stiffness
- noradrenaline — primary sympathetic neurotransmitter; higher affinity for α and β1 than β2 receptors
- adrenaline — adrenal medulla hormone; preferentially activates β2 receptors; equal affinity for β1
- sympathetic nervous system — adrenoreceptors are the molecular effectors of sympathetic signaling across all organs
- GPCR — adrenoreceptors belong to this receptor superfamily coupling to G-proteins (Gq, Gi, Gs)
- stress response — acute sympathetic activation via adrenoreceptors redistributes blood flow, mobilizes energy, recruits immune cells
- Calcium — α1-receptor signaling increases intracellular Ca²⁺ via IP₃-mediated release; drives vasoconstriction and tissue contractility
- CAMP — β-receptors increase cAMP (via Gs); α2-receptors decrease cAMP (via Gi)—opposing second messenger effects
- PKA — downstream effector of β-receptor cAMP signaling; phosphorylates cardiac proteins, metabolic enzymes
- Lipolysis — β2 and β3 activation via PKA → hormone-sensitive lipase phosphorylation → free fatty acid release
- thermoregulation — β3 in brown fat activates UCP1 → non-shivering thermogenesis
- chronic stress — chronic adrenoreceptor activation → downregulation and resistance; connective tissue stiffening via α1
- Catecholamine Resistance — consequence of chronic receptor stimulation; seen in heart failure, chronic stress, metabolic syndrome
- connective tissue — fascial myofibroblasts express α1-adrenoreceptors; sympathetic tone increases tissue tension and stiffness
- heart failure — characterized by β1-receptor downregulation and catecholamine resistance; β-blockers paradoxically therapeutic
- asthma — β2-agonists are first-line bronchodilators; Gly16Arg polymorphism affects treatment response
- insulin resistance — chronic sympathetic activation via β-receptors impairs insulin signaling; α2 inhibits insulin secretion
- HRV — reflects sympathetic-parasympathetic balance; low HRV indicates sympathetic dominance and poor receptor regulation
- brown adipose tissue — express β3-adrenoreceptors; cold exposure → noradrenaline → thermogenesis
- fibromyalgia — may involve chronic fascial tension from sympathetic dominance and α1-mediated myofibroblast contraction
- PTSD — characterized by sympathetic hyperarousal; elevated catecholamines and potential receptor dysregulation
- migraine — β-blockers (propranolol) used prophylactically; mechanism may involve reduced sympathetic tone and vascular reactivity
- allostatic load — chronic adrenoreceptor activation contributes to cumulative physiological wear-and-tear
- Module 5 (primary reference: sympathetic signaling, catecholamines, receptor pharmacology, connective tissue effects)